Precigen, Inc. (NASDAQ:PGEN) CEO Helen Sabzevari sold 12,531 shares of Precigen stock in a transaction on Monday, July 19th. The shares were sold at an average price of $5.43, for a total transaction of $68,043.33. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Helen Sabzevari also recently made the following trade(s):
- On Thursday, May 13th, Helen Sabzevari sold 47,433 shares of Precigen stock. The shares were sold at an average price of $6.40, for a total transaction of $303,571.20.
Shares of NASDAQ PGEN opened at $5.72 on Thursday. The company has a fifty day moving average of $6.47. Precigen, Inc. has a 52-week low of $3.36 and a 52-week high of $11.10. The company has a debt-to-equity ratio of 1.00, a quick ratio of 5.29 and a current ratio of 5.71. The company has a market cap of $1.18 billion, a P/E ratio of -7.53 and a beta of 2.32.
Several institutional investors have recently bought and sold shares of PGEN. New York State Common Retirement Fund increased its holdings in shares of Precigen by 1,422.4% in the 1st quarter. New York State Common Retirement Fund now owns 858,632 shares of the biotechnology company’s stock worth $5,916,000 after buying an additional 802,232 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Precigen by 10.9% during the 1st quarter. BlackRock Inc. now owns 7,375,625 shares of the biotechnology company’s stock worth $50,816,000 after purchasing an additional 726,353 shares during the period. Morgan Stanley purchased a new position in shares of Precigen during the 1st quarter worth about $2,245,000. Citigroup Inc. boosted its stake in shares of Precigen by 1,280.4% during the 1st quarter. Citigroup Inc. now owns 496,961 shares of the biotechnology company’s stock worth $3,424,000 after purchasing an additional 460,959 shares during the period. Finally, Norges Bank purchased a new position in shares of Precigen during the 4th quarter worth about $4,154,000. Hedge funds and other institutional investors own 68.61% of the company’s stock.
A number of research analysts recently weighed in on the stock. Zacks Investment Research upgraded shares of Precigen from a “sell” rating to a “hold” rating in a research note on Wednesday, April 21st. HC Wainwright reiterated a “buy” rating on shares of Precigen in a report on Tuesday, May 11th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Precigen presently has a consensus rating of “Buy” and an average price target of $11.25.
Precigen Company Profile
Precigen, Inc discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; proprietary methane bioconversion platform that turns natural gas into energy and chemical products; and reproductive and embryo transfer technologies.
Featured Article: What Every Investor Needs to Understand About Secondary Public Offerings
Receive News & Ratings for Precigen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precigen and related companies with MarketBeat.com's FREE daily email newsletter.